2022 Partners

We would like to thank all our 2022 partners for choosing to support the Neoantigen Summit Europe.

Find out more about each of our sponsors by reading their summary biographies or visiting their websites. To learn about our bespoke partnership opportunities and how you can get your brand in front of our dedicated neoantigen audience, view our why partner page, download the 2022 event guide or get in touch with us.

Personalis

EXPERTISE PARTNER:

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited.

www.personalis.com

download

EXPERTISE PARTNER:

Cayman’s Immunology and Cellular Metabolism Services can complement your drug discovery efforts. Our Immunopeptidome Profiling Services enable deep sequencing analysis of MHC associated peptides by LC-MS/MS, allowing neoantigen identification in cell lines and tumor tissue. Our Cellular Metabolism Services measure the metabolic response of cells to therapeutics under a wide range of customizable in vitro metabolic environments. Cayman’s expertise in cell culture, immunoassays, antibodies, and assay development provides a complete solution for your research needs.

www.caymanchem.com

NEC Oncolmmunity

INDUSTRY PARTNER:

NEC OncoImmunity is a bioinformatics company offering proprietary machinelearning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neo-antigens for personalized cancer immunotherapy. NEC OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in clinically actionable time-frame.

www.oncoimmunity.com

Intomics

INDUSTRY PARTNER:

Intomics was founded by world-leading scientists within the field of bioinformatics and systems biology to accelerate and improve drug discovery and development. We are biologists, bioinformaticians, data scientists and software engineers that share a passion for translating data to cures. And we’ve proudly done so for more than 10 years. 

We collaborate closely with our clients in the biotech & pharmaceutical industry, and exploit the synergy between our clients’ specific disease knowledge and our unique data analytics expertise and technology. Together we make a difference for patients. This is both our trademark & what drives the people of Intomics.

www.intomics.com

BCN Peptides

EXHIBITION PARTNER:

BCN peptides is an industrial manufacturer with the capacity to produce from milligrams up to multi-kg bulk commercial quantities of GMP pharmaceutical peptides. We have designed and equipped with state-of-the-art technology to meet the unique requirements of neoantigens production. The implementation of automatization systems, together with a fit-for-purpose quality system allows for high-speed production and fully compliant GMP manufacturing with complete traceability of the entire process. We are flexible to meet each customer's specific demands and we are totally aware of our role as a critical partner in your project. Our participation supplying personalized neoantigen peptides in multiple clinical trials together with our track record and positive regulatory audit reviews from authorities, makes us your partner of choice in the production of Neoantigen Peptides.

BCN Peptides - Your partner of choice in the production of Neoantigen Peptides for Immunotherapy

www.bcnpeptides.com

PathoQuest

EXHIBITION PARTNER:

Robust and efficient Quality Control testing is critical for the development of personalized cancer vaccines and immunotherapies in order to reduce time to market and improve patient outcomes. Developers, producers need QC testing which help de-risk their product development pipeline by preventing adventitious agent contamination and cell lines misidentification. To meet those objectives, PathoQuest offers advanced Next Generation Sequencing (NGS) solutions that supplement or replace traditional methods and support the strategic decision-making process. This innovative approach allows for robust and unambiguous level of testing and for faster turnaround time.

www.pathoquest.com

EXHIBITION PARTNER:

As a preeminent peptide supplier Pepscan, based in the Netherlands, has enabled life-improving breakthroughs for 25 years. Our services cover the full range of personalized peptides, from neoantigen libraries for T-Cell stimulation to GMP compliant neoantigen peptide pools. Pepscan is supplier for various personalized medicine trials in phases 1 and 2b in Europe, the United States and Australia.  For precision medicine, we offer peptide drug discovery services using our proprietary CLIPSTM technology in phage display campaigns and lead optimization programs.

www.pepscan.com/personalized-peptides

 

EXHIBITION PARTNER:

Provepharm is an affiliated company of the privately-held Provence Technologies Group, devoted to develop and market drugs made from pharmaceutical active substances (or API) synthesized and patented by its parent company, and licence and market such API to third parties, for human health applications.

Provepharm’s expertise is stemming from experienced managers coming from the international pharmaceutical & medical device industries and enthusiastic project managers focusing on rewarding results.

www.provepharm.com/en

Almac

EXHIBITION PARTNER:

Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personalized cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.

www.almacgroup.com